Highlights OSE Immunotherapeutics

Equities

OSE

FR0012127173

Market Closed - Euronext Paris Other stock markets 09:05:26 26/06/2024 pm IST			5-day change	1st Jan Change
6.05 ^EUR	+2.20%		+3.42%	+41.36%

24/06	OSE: market welcomes CAR-T agreement	CF
24/06	OSE Immunotherapeutics SA Enters into a Commercial and Revenue Sharing Agreement with Memorial Sloan Kettering Cancer Center	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OSE: market welcomes CAR-T agreement	24/06	CF
OSE Immunotherapeutics SA Enters into a Commercial and Revenue Sharing Agreement with Memorial Sloan Kettering Cancer Center	24/06	CI
OSE: treatment prospects with therapeutic mRNA	20/06	CF
OSE Immunotherapeutics Presents Preclinical Data on Mrna Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders At the Focis Annual Meeting, San Francisco	20/06	CI
OSE Immuno: positive analysis presented at ATC congress	05/06	CF
OSE Immuno: towards an evolution of the Board of Directors	30/05	CF
OSE, Boehringer Ingelheim Expand Partnership for Immuno-oncology Programs	22/05	MT
OSE: agreement extended with Boehringer Ingelheim, share price rises	22/05	CF
OSE Immunotherapeutics SA and Boehringer Ingelheim Expand Collaboration to Develop First-In-Class Treatments for Cancer and Cardio-Renal-Metabolic Diseases	22/05	CI
OSE: licensing agreement with AbbVie enters into force	17/04	CF
OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie	17/04	MT
OSE Immunotherapeutics SA's Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective	16/04	CI
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	11/04
Ose Immuno receives funding from Bpifrance	11/04	CF
OSE Immunotherapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
OSE IMMUNOTHERAPEUTICS : Degroof Petercam reiterates buy recommendation	18/03	CF
OSE Immuno: recruitment completed for UC trial	18/03	CF
Ose Immunotherapeutics Sa Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis	18/03	CI
OSE Immuno: share price soars following partnership with AbbVie	28/02	CF
OSE Immunotherapeutics, AbbVie Partner on Chronic Inflammation Monoclonal Antibody	28/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights OSE Immunotherapeutics

Equities

OSE

FR0012127173

Highlights

Filters